influenza messenger ribonucleic acid vaccine

The influenza messenger ribonucleic acid vaccine is an investigational prophylactic vaccine developed by RNACure Biopharma using its proprietary mRNA technology platform. The vaccine is designed to deliver messenger RNA encoding specific influenza virus antigens into host cells. Once inside, the host's cellular machinery translates the mRNA into viral proteins, which then elicit a comprehensive immune response involving both neutralizing antibodies and T-cell activation. This mRNA-based approach offers potential advantages over traditional vaccine manufacturing, including faster production timelines and the ability to rapidly update the vaccine sequence to match circulating seasonal or pandemic strains.

Other names

influenza mRNA vaccineRNACure influenza vaccine